Jeffrey Miller, MD Professor of Medicine and Director of Clinical Endocrinology and Diabetes Division of Endocrinology, Diabetes and Metabolism Thomas Jefferson University Hospital and Jefferson Medical College Philadelphia, PA
Serena Cardillo, MD Assistant Professor of Medicine Division of Endocrinology, Diabetes & Metabolism Hospital of the University of Pennsylvania Philadelphia, PA John J. Russell, MD Director of Family Medicine Residency Abington Memorial Hospital Clinical Associate Professor of Family and Community Medicine Temple University School of Medicine Jenkintown, PA
CCME Reviewer Joel Zonszein, MD, CDE, FACE, FACP Professor of Clinical Medicine, Albert Einstein College of Medicine Clinical Diabetes Center, Montefiore Medical Center Bronx, NY
Type 2 diabetes has reached an epidemic level in the United States. Management of the condition remains a major clinical challenge with only half of patients achieving their recommended glycemic goals. An emerging new class of agents to reduce hyperglycemia, sodium-glucose transporter 2 (SGLT2) inhibitors, offers the potential to improve glycemic control for many patients with type 2 diabetes through a novel mechanism of action. SGLT2 inhibitors reduce hyperglycemia by blocking renal glucose reabsorption. The goal of this continuing medical education activity is to prepare endocrinologists and primary care clinicians to appropriately incorporate SGLT2 inhibitors into type 2 diabetes treatment regimens when available, ultimately helping patients achieve better glycemic control.
This activity is jointly provided by Albert Einstein College of Medicine and Montefiore Medical Center, and MCM Education.
Endocrinologists, nephrologists, internal medicine and primary care clinicians, and other healthcare providers interested and involved in the treatment of patients with diabetes.
Upon completion of this educational activity, the participant should be able to:
Compare the mechanism of action of sodium-glucose cotransporter-2 (SGLT2) inhibitors with other agents used in type 2 diabetes.
Review the most current data on the safety, efficacy, and tolerability of SGLT2 inhibitors when used as monotherapy or in combination regimens for treatment of type 2 diabetes.
Describe the effects of SGLT2 inhibitors on other cardiovascular risk factors such as blood pressure, lipid profile, and body weight/waist circumference.
Summarize ongoing clinical trials of SGLT2 inhibitors in patients with type 2 diabetes.
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical, product, or device company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present. Albert Einstein College of Medicine and MCM Education. staff have no conflicts of interest with commercial interests related directly or indirectly to this educational activity.
Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product not yet approved for use in the United States.
Dr. Miller discloses that he has served as a consultant for Boehringer Ingelheim and Eli Lilly and Company and received grant/research funding from Amgen.
Dr. Cardillo discloses that she has received grant/research funding from Bristol Myers Squibb and AstraZeneca.
Dr. Russell discloses that he has served on the speakers bureau for SanofiPasteur.
Dr. Zonszein discloses that he has served on speakers bureaus for Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.; Merck/Schering-Plough Pharmaceuticals; and Sanofi-Aventis. He has also served on an advisory panel for Takeda Pharmaceuticals North America, Inc.
The staff of CCME of Albert Einstein College of Medicine have no disclosures to report with any commercial interests other than the following:
Steven Jay Feld, or a member of his household, own securities in: Bioheart Inc.; Chelsea Therapeutics, Inc.; and Pharmacopeia, Inc.
Kathleen Hines (MCM Education medical editor) has no disclosures. Credit Statements
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine, Montefiore Medical Center and MCM Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s) TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit is awarded to participants who score 60% or better on the post-test.
This activity will take approximately 60 minutes to complete.
Commercial Support Statements
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc., which was made possible, in part, through collaboration with Eli Lilly and Company.
Please turn off all pop-up blockers to assure access to the educational activity.
Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 60 minutes to complete.
After the activity has finished, click on the "Post-test" button.
Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen.
iPad and iPhone Users
Before Starting Program:
Please be sure to download Xyvid app. You must launch the program from this application, not from this landing page.
- If you don’t already have it, download the Xyvid app from iTunes before webcast.
- If you have the Xyvid app, please check the app store to make sure you have the latest version.
To Start Program:
Please connect via a strong Wi-Fi connection (3G is not recommended) buffering will occur.
Be sure to shut off VPN. Go to settings > General > VPN turn off, then Launch the Xyvid app
Once in the Xyvid application, press the continue button (not “view demo”) to enter the iPad Meeting ID: diabetesvrt099
Ensure that the volume is up on your iPad/iPhone.
- Should you encounter a “frozen” screen, please terminate the Xyvid App. To do this, double click on your home button and hold finger over the Xyvid app until the icons jiggles. Tap the “minus” sign to exit the application – press the home button twice and restart the Xyvid App. Following instructions above.
Presented by Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, and MCM Education.
The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, Boehringer Ingelheim, or Eli Lilly and Company. Any medications, diagnostic procedures, or treatments discussed by the presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.